Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Receivables (2016 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 15 years of Receivables data on record, last reported at $22.1 million in Q2 2025.

  • For Q2 2025, Receivables rose 48.73% year-over-year to $22.1 million; the TTM value through May 2025 reached $22.1 million, up 48.73%, while the annual FY2025 figure was $22.1 million, 48.73% up from the prior year.
  • Receivables reached $22.1 million in Q2 2025 per LFCR's latest filing, up from $17.5 million in the prior quarter.
  • Across five years, Receivables topped out at $53.6 million in Q1 2022 and bottomed at $14.9 million in Q3 2023.
  • Average Receivables over 5 years is $32.8 million, with a median of $35.8 million recorded in 2022.
  • Peak YoY movement for Receivables: crashed 66.77% in 2023, then surged 101.61% in 2024.
  • A 5-year view of Receivables shows it stood at $40.1 million in 2021, then dropped by 10.57% to $35.9 million in 2022, then plummeted by 37.72% to $22.3 million in 2023, then skyrocketed by 63.73% to $36.6 million in 2024, then tumbled by 39.47% to $22.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $22.1 million in Q2 2025, $17.5 million in Q1 2025, and $36.6 million in Q4 2024.